424 related articles for article (PubMed ID: 15687498)
1. Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells.
Wang J; Boxer LM
J Biol Chem; 2005 Apr; 280(13):12766-73. PubMed ID: 15687498
[TBL] [Abstract][Full Text] [Related]
2. In a model of immunoglobulin heavy-chain (IGH)/MYC translocation, the Igh 3' regulatory region induces MYC expression at the immature stage of B cell development.
Yan Y; Park SS; Janz S; Eckhardt LA
Genes Chromosomes Cancer; 2007 Oct; 46(10):950-9. PubMed ID: 17639584
[TBL] [Abstract][Full Text] [Related]
3. The immunoglobulin heavy chain gene 3' enhancers induce Bcl2 deregulation and lymphomagenesis in murine B cells.
Xiang H; Noonan EJ; Wang J; Duan H; Ma L; Michie S; Boxer LM
Leukemia; 2011 Sep; 25(9):1484-93. PubMed ID: 21606958
[TBL] [Abstract][Full Text] [Related]
4. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Emu).
Palomo C; Zou X; Nicholson IC; Bützler C; Brüggemann M
Cancer Res; 1999 Nov; 59(21):5625-8. PubMed ID: 10554044
[TBL] [Abstract][Full Text] [Related]
5. NF-kappa B activity is required for the deregulation of c-myc expression by the immunoglobulin heavy chain enhancer.
Kanda K; Hu HM; Zhang L; Grandchamps J; Boxer LM
J Biol Chem; 2000 Oct; 275(41):32338-46. PubMed ID: 10931834
[TBL] [Abstract][Full Text] [Related]
6. The 3' IgH locus control region is sufficient to deregulate a c-myc transgene and promote mature B cell malignancies with a predominant Burkitt-like phenotype.
Truffinet V; Pinaud E; Cogné N; Petit B; Guglielmi L; Cogné M; Denizot Y
J Immunol; 2007 Nov; 179(9):6033-42. PubMed ID: 17947677
[TBL] [Abstract][Full Text] [Related]
7. The immunoglobulin heavy-chain gene 3' enhancers deregulate bcl-2 promoter usage in t(14;18) lymphoma cells.
Duan H; Heckman CA; Boxer LM
Oncogene; 2007 Apr; 26(18):2635-41. PubMed ID: 17043638
[TBL] [Abstract][Full Text] [Related]
8. Mouse Models of
Ferrad M; Ghazzaui N; Issaoui H; Cook-Moreau J; Denizot Y
Front Immunol; 2020; 11():1564. PubMed ID: 32793219
[TBL] [Abstract][Full Text] [Related]
9. A p53 defect sensitizes various stages of B cell development to lymphomagenesis in mice carrying an IgH 3' regulatory region-driven c-myc transgene.
Fiancette R; Rouaud P; Vincent-Fabert C; Laffleur B; Magnone V; Cogné M; Denizot Y
J Immunol; 2011 Dec; 187(11):5772-82. PubMed ID: 22039300
[TBL] [Abstract][Full Text] [Related]
10. A myeloma translocation-like model associating CCND1 with the immunoglobulin heavy-chain locus 3' enhancers does not promote by itself B-cell malignancies.
Fiancette R; Amin R; Truffinet V; Vincent-Fabert C; Cogné N; Cogné M; Denizot Y
Leuk Res; 2010 Aug; 34(8):1043-51. PubMed ID: 20018375
[TBL] [Abstract][Full Text] [Related]
11. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
12. The IgH 3' regulatory region and c-myc-induced B-cell lymphomagenesis.
Ghazzaui N; Saintamand A; Issaoui H; Vincent-Fabert C; Denizot Y
Oncotarget; 2017 Jan; 8(4):7059-7067. PubMed ID: 27729620
[TBL] [Abstract][Full Text] [Related]
13. A Myc-associated zinc finger protein-related factor binding site is required for the deregulation of c-myc expression by the immunoglobulin heavy chain gene enhancers in Burkitt's lymphoma.
Hu HM; Arcinas M; Boxer LM
J Biol Chem; 2002 Mar; 277(12):9819-24. PubMed ID: 11777933
[TBL] [Abstract][Full Text] [Related]
14. Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells.
Madisen L; Groudine M
Genes Dev; 1994 Sep; 8(18):2212-26. PubMed ID: 7958890
[TBL] [Abstract][Full Text] [Related]
15. Bax loss impairs Myc-induced apoptosis and circumvents the selection of p53 mutations during Myc-mediated lymphomagenesis.
Eischen CM; Roussel MF; Korsmeyer SJ; Cleveland JL
Mol Cell Biol; 2001 Nov; 21(22):7653-62. PubMed ID: 11604501
[TBL] [Abstract][Full Text] [Related]
16. Variable IgH chain enhancer activity in Burkitt's lymphomas suggests an additional, direct mechanism of c-myc deregulation.
Jain VK; Judde JG; Max EE; Magrath IT
J Immunol; 1993 Jun; 150(12):5418-28. PubMed ID: 8515068
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
[TBL] [Abstract][Full Text] [Related]
18. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
19. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
20. Regulatory elements in the immunoglobulin kappa locus induce c-myc activation and the promoter shift in Burkitt's lymphoma cells.
Polack A; Feederle R; Klobeck G; Hörtnagel K
EMBO J; 1993 Oct; 12(10):3913-20. PubMed ID: 8404859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]